These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27628221)

  • 41. Myocardial contractile dysfunction associated with increased 3-month and 1-year mortality in hospitalized patients with heart failure and preserved ejection fraction.
    Zhong L; Ng KK; Sim LL; Allen JC; Lau YH; Sim DK; Lee RK; Poh KK; Chua TS; Kassab GS; Kwok BW; Tan RS
    Int J Cardiol; 2013 Oct; 168(3):1975-83. PubMed ID: 23336957
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Heart failure with preserved left ventricular ejection fraction].
    Maeder MT; Rickli H
    Praxis (Bern 1994); 2013 Oct; 102(21):1299-307. PubMed ID: 24129298
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial.
    Rector TS; Carson PE; Anand IS; McMurray JJ; Zile MR; McKelvie RS; Komajda M; Kuskowski M; Massie BM;
    Circ Heart Fail; 2012 Mar; 5(2):217-25. PubMed ID: 22267751
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction: a dose-response meta-analysis.
    Zhang J; Begley A; Jackson R; Harrison M; Pellicori P; Clark AL; Cleland JGF
    Clin Res Cardiol; 2019 Feb; 108(2):119-132. PubMed ID: 29951802
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Left Ventricular Ejection Fraction (EF) of 55% as Cutoff for Late Transition From Heart Failure (HF) With Preserved EF to HF With Mildly Reduced EF.
    Ueda T; Kawakami R; Nishida T; Onoue K; Soeda T; Okayama S; Takeda Y; Watanabe M; Kawata H; Uemura S; Saito Y
    Circ J; 2015; 79(10):2209-15. PubMed ID: 26227392
    [TBL] [Abstract][Full Text] [Related]  

  • 46. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction.
    van Veldhuisen DJ; Linssen GC; Jaarsma T; van Gilst WH; Hoes AW; Tijssen JG; Paulus WJ; Voors AA; Hillege HL
    J Am Coll Cardiol; 2013 Apr; 61(14):1498-506. PubMed ID: 23500300
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND.
    Brouwers FP; de Boer RA; van der Harst P; Voors AA; Gansevoort RT; Bakker SJ; Hillege HL; van Veldhuisen DJ; van Gilst WH
    Eur Heart J; 2013 May; 34(19):1424-31. PubMed ID: 23470495
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Depressive symptoms are common and associated with adverse clinical outcomes in heart failure with reduced and preserved ejection fraction.
    Kato N; Kinugawa K; Shiga T; Hatano M; Takeda N; Imai Y; Watanabe M; Yao A; Hirata Y; Kazuma K; Nagai R
    J Cardiol; 2012 Jul; 60(1):23-30. PubMed ID: 22445598
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of risk factors for acute worsening renal function in heart failure patients with and without preserved ejection fraction.
    Yamagishi T; Matsushita K; Minamishima T; Goda A; Sakata K; Satoh T; Yoshino H
    Eur J Intern Med; 2015 Oct; 26(8):599-602. PubMed ID: 26298856
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy.
    Krum H; Elsik M; Schneider HG; Ptaszynska A; Black M; Carson PE; Komajda M; Massie BM; McKelvie RS; McMurray JJ; Zile MR; Anand IS
    Circ Heart Fail; 2011 Sep; 4(5):561-8. PubMed ID: 21750125
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial.
    Zile MR; Gaasch WH; Anand IS; Haass M; Little WC; Miller AB; Lopez-Sendon J; Teerlink JR; White M; McMurray JJ; Komajda M; McKelvie R; Ptaszynska A; Hetzel SJ; Massie BM; Carson PE;
    Circulation; 2010 Mar; 121(12):1393-405. PubMed ID: 20231531
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
    Ohishi M; Takeya Y; Tatara Y; Yamamoto K; Onishi M; Maekawa Y; Kamide K; Rakugi H
    Hypertens Res; 2010 Nov; 33(11):1150-4. PubMed ID: 20703230
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
    Fliser D; Buchholz K; Haller H;
    Circulation; 2004 Aug; 110(9):1103-7. PubMed ID: 15313950
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction.
    Kasama S; Toyama T; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
    J Am Coll Cardiol; 2005 Mar; 45(5):661-7. PubMed ID: 15734608
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcomes in World Health Organization group II pulmonary hypertension: mortality and readmission trends with systolic and preserved ejection fraction-induced pulmonary hypertension.
    Salamon JN; Kelesidis I; Msaouel P; Mazurek JA; Mannem S; Adzic A; Zolty R
    J Card Fail; 2014 Jul; 20(7):467-75. PubMed ID: 24858070
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
    van Veldhuisen DJ; Cohen-Solal A; Böhm M; Anker SD; Babalis D; Roughton M; Coats AJ; Poole-Wilson PA; Flather MD;
    J Am Coll Cardiol; 2009 Jun; 53(23):2150-8. PubMed ID: 19497441
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of Beta-blocker therapy on rehospitalization rates in women versus men with heart failure and preserved ejection fraction.
    Farasat SM; Bolger DT; Shetty V; Menachery EP; Gerstenblith G; Kasper EK; Najjar SS
    Am J Cardiol; 2010 Jan; 105(2):229-34. PubMed ID: 20102924
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction.
    Savarese G; Edner M; Dahlström U; Perrone-Filardi P; Hage C; Cosentino F; Lund LH
    Int J Cardiol; 2015 Nov; 199():415-23. PubMed ID: 26247798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.